
PHARMACEUTICAL 2017

XOMA Corp Rank 246 of 313







PHARMACEUTICAL 2017

XOMA Corp Rank 246 of 313



The relative strengths and weaknesses of XOMA Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Corp compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 74% points. The greatest weakness of XOMA Corp is the variable Research and Development, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -515%, being 98% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	27,160
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,506
Liabilities, Non-Current	25,381
Other Assets	481
Other Compr. Net Income	0
Other Expenses	-1,952
Other Liabilities	18,000
Other Net Income	0
Property and Equipment	1,036
Research and Development	44,234
Revenues	7,074
Selling, General and Administrative Expense	18,322

Output Variable	Value in 1000 USD
Assets	28,677
Liabilities	75,887
Expenses	60,604
Stockholders Equity	-47,210
Net Income	-53,530
Comprehensive Net Income	-53,530
Economic Capital Ratio	-515%